Here's the pdf for this presentation: Inherited T790M EGFR Mutation

Since the introduction of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for patients with lung cancer, we have seen a subset of patients do remarkably well, with dramatic and long lasting responses. Unfortunately, within a few months of those impressive responses, we learned that people invariably develop acquired resistance to these agents.

With the recent approval of afatinib, now becoming commercially available as Gilotrif, there is the potential new strategy for patients with an EGFR mutation who develop acquired resistance to a different EGFR tyrosine kinase inhibitor (TKI) in an earlier line of therapy.

Dr. Greg Riely, from Memorial Sloan-Kettering, describes which patients with advanced NSCLC he seeks molecular marker testing on, and the particular markers he prioritizes.

[powerpress]

Dr. Phil Bonomi, from Rush University, describes the generations of EGFR inhibitors beginning with Gefitinib (Iressa).

[powerpress]

Afatinib, newly christened Gilotrif, is the newest EGFR tyrosine kinase inhibitor (TKI) approved by the FDA, specifically for patients with an EGFR mutation as first line therapy.

Dr. David Spigel, Sarah Cannon Cancer Center, describes which molecular markers he seeks for NSCLC patients.

[powerpress]

Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Drs. Ross Camidge and Corey Langer describe which patients with advanced NSCLC they seek molecular marker testing on.

[powerpress]

Dr. Phil Bonomi, from Rush University, reviews his thought process in recommending a repeat biopsy after progression for patients with advanced lung cancer.

[powerpress]